raloxifene hydrochloride has been researched along with Blood Clot in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, H; Xi, S; Xu, L | 1 |
| Hanai, Y; Kozawa, O; Matsushima-Nishiwaki, R; Minamitani, C; Otuka, T; Takai, S; Tokuda, H | 1 |
| Azevedo, GD; Baggio, MS; Franco, RF; Maranhão, TM; Sá, MF | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Berg, DT; Calnek, DS; Ciaccia, AV; Grinnell, BW; Joyce, DE; Richardson, MA | 1 |
| Birkhäuser, MH | 1 |
| Emons, G; Westphalen, S | 1 |
1 review(s) available for raloxifene hydrochloride and Blood Clot
| Article | Year |
|---|---|
[Indications for hormone replacement therapy].
Topics: Aged; Alzheimer Disease; Anabolic Agents; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Thrombosis | 2000 |
2 trial(s) available for raloxifene hydrochloride and Blood Clot
| Article | Year |
|---|---|
Procoagulant state after raloxifene therapy in postmenopausal women.
Topics: Blood Coagulation; Blood Coagulation Factors; Female; Fibrinogen; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Peptide Fragments; Postmenopause; Prospective Studies; Protein C; Protein Precursors; Prothrombin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thrombosis | 2005 |
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms | 2006 |
5 other study(ies) available for raloxifene hydrochloride and Blood Clot
| Article | Year |
|---|---|
[Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Topics: Animals; Antithrombin III; Disease Models, Animal; Estrogens, Conjugated (USP); Female; Fibrinogen; Fibrinolysis; Ovariectomy; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Sprague-Dawley; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis | 2013 |
Raloxifene-induced acceleration of platelet aggregation.
Topics: Blood Platelets; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Phosphorylation; Platelet Aggregation; Raloxifene Hydrochloride; Signal Transduction; Thrombosis | 2008 |
My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug
Topics: Bone Density Conservation Agents; Diet; Exercise; Female; Humans; Hypertension; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Thrombosis | 2010 |
17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway.
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Humans; Protein C; Pyrrolidines; Raloxifene Hydrochloride; Thiophenes; Thrombomodulin; Thrombosis; Umbilical Veins | 2000 |
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors | 2002 |